231 related articles for article (PubMed ID: 34509404)
1. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
[TBL] [Abstract][Full Text] [Related]
2. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
3. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
4. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
8. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
10. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
[TBL] [Abstract][Full Text] [Related]
12. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
13. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Mitter SS; Shah SJ
Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
[TBL] [Abstract][Full Text] [Related]
17. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Shah SJ; Heitner JF; Sweitzer NK; Anand IS; Kim HY; Harty B; Boineau R; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Lewis EF; Markov V; O'Meara E; Kobulia B; Shaburishvili T; Solomon SD; Pitt B; Pfeffer MA; Li R
Circ Heart Fail; 2013 Mar; 6(2):184-92. PubMed ID: 23258572
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Kalra R; Gupta K; Sheets R; Aryal S; Ebrahimi A; Rajapreyar I; Cribbs MG; Booker OJ; Prabhu SD; Bajaj NS
Am J Cardiol; 2020 Aug; 129():46-52. PubMed ID: 32563496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
